Rebalance Health’s Groundbreaking Study Shows 90% Reduction in Menopausal Symptoms
Rebalance Health, a leading health and wellness company, has recently revealed preliminary findings from an IRB-approved open-label study, marking a significant advancement in women’s health. The study, detailed in the North American Menopause Society’s Menopause Journal, indicates a substantial 90% reduction in menopausal symptoms. The comprehensive outcomes of this study are scheduled for release in the first quarter.
At the core of Rebalance Health’s breakthrough is a proprietary system targeting cortisol levels, aiding natural rebalancing without resorting to hormone replacement therapy. Administered three times a day, the formulation optimizes the body’s cortisol levels in harmony with its metabolic rhythms.
Conducted by Dr. Todd Dorfman, Rebalance Health’s Chief Medical Officer, the IRB-approved study engaged 101 women, averaging 53 years of age, from diverse backgrounds. These participants, who hadn’t used hormone therapy in the past year and experienced hot flashes, received a 90-day supply of The Hot Flash System—comprising three daily lozenges. Regularly reporting hot flashes and daily feedback, they consented to four blood draws, enabling the study to measure hormonal variations and menopausal parameters.
The pivotal results speak volumes:
- 90% of participants reported a substantial reduction in menopausal symptoms.
- 80% observed a significant decrease in hot flashes and other symptoms.
- 25% experienced complete elimination of hot flashes.
Participants further reported enhancements in sleep quality, energy levels, mood, libido, mental clarity, workout recovery, skin health, and nail strength.
Justin Hai, Founder, President, and CEO of Rebalance Health, expressed gratitude for the study’s publication in the North American Menopause Society and emphasized their product’s transformative potential for millions of women grappling with menopausal symptoms. Reflecting on his wife’s diagnosis with Cushing’s and the subsequent pursuit of a natural solution, Hai underscored the rewarding impact on consumers’ lives.
The study also highlights that Rebalance Health’s delivery system significantly augments estradiol levels while alleviating vasomotor symptoms in menopausal women over time. Compared to market competitors, their Directline® technology showcased a 300% increase in serum levels and a 60% longer duration, affirming its efficacy.
The Hot Flash System is available for monthly ($63.75), quarterly ($180), or one-time ($75) purchases on rebalancehealth.com. Free from fillers, additives, dyes, gluten, soy, and whey, Rebalance Health’s products are vegan-friendly and expertly formulated. Anticipated for Q1 2024, a comprehensive study publication is set to reveal unprecedented insights beyond the NAMS abstract.
About Rebalance Health: Initiated by Justin Hai’s quest to aid his wife diagnosed with Cushing’s, Rebalance Health’s mission centers on comprehensive hormonal support. Their Rebalance Systems™ offers three distinct lozenges tailored for managing hot flashes, anxiety, or testosterone levels throughout the day and night.
